Advertisement

Topics

Affibody Company Profile

22:12 EST 16th December 2018 | BioPortfolio

Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has obtained outstanding clinical molecular imaging results and promising targeted therapeutics pre-clinical results. Affibody expects to launch one molecular imaging agent per year from 2007 and to file one targeted therapeutics IND every second year.

Location

Voltavägen 13,floor 5
Bromma
SE-168 69
Sweden

Contact

Phone: 46 (0) 8 598 838 00
Fax: 46 (0) 8 598 838 01
Email: reception@affibody.com


News Articles [9 Associated News Articles listed on BioPortfolio]

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic stud...

Beyond antibodies. Are Affibody poised to make the next significant biologics breakthrough?

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. During NLSD in...

Affibody announces option exercise by Biotest

Affibody, a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, announces that its partner Biotest, a biotherapeutic company, has exercised an option under the...

Biotest extends option for new haemophilia product with Affibody

Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner...

Novel Pretargeted Radionucleotide Therapy for HER2-Expressing Cancers Show Promise

NewsIn a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers is non-toxic to the kidneys and improves survival.

Affibody AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12042018] Prices from USD $250

SummaryAffibody AB Affibody is a biotech company that develops next generation biopharmaceuticals. The company develops drugs based on its proprietary technology platforms such as Affibody molecules a...

Affibody AB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryAffibody AB Affibody is a biotech company that discovers and develops next generation biopharmaceuticals and related drugs. The company discovers and develops drugs based on its proprietary tec...

Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise

(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth facto...

Drugs and Medications [0 Results]

None

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Autotransporter-mediated display of a naïve affibody library on the outer membrane of E. coli.

Development of new affinity proteins using combinatorial protein engineering is today established for generation of monoclonal antibodies and also essential for discovery of binders that are based on ...

Evaluation of the therapeutic potential of a HER3-binding affibody construct TAM-HER3 in comparison with a monoclonal antibody, seribantumab.

Human epidermal growth factor receptor type 3 (HER3) is recognized to be involved in resistance to HER-targeting therapies. A number of HER3-targeting monoclonal antibodies are under clinical investig...

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.

Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules, which are small affinity proteins which can be engineer...

Engineering Tunable Dual Functional Protein Cage Nanoparticles Using Bacterial Superglue.

The selective detection of specific cells of interest and their effective visualization is important but challenging, and fluorescent cell imaging with target-specific probes is commonly used to visua...

Synergistic Enhancement of Enzyme Performance and Resilience via Orthogonal Peptide-Protein Chemistry Enabled Multilayer Construction.

Protein immobilization is critical to utilize their unique functions in diverse applications. Herein, we report that orthogonal peptide-protein chemistry enabled multilayer construction can facilitate...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule

The investigators developed [68Ga]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.

In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule

The investigators developed [68Ga]-labelling Anti-EGFR Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-ECD expression status.

99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the diagnostic performance and evaluation efficacy of 99mTc-ABH2 in breast cance...

A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer (Affibody-3).

A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out th...

Companies [1 Associated Companies listed on BioPortfolio]

Affibody

Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has ...

More Information about "Affibody" on BioPortfolio

We have published hundreds of Affibody news stories on BioPortfolio along with dozens of Affibody Clinical Trials and PubMed Articles about Affibody for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Affibody Companies in our database. You can also find out about relevant Affibody Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record